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Abstract
Positron emission tomography (PET) and magnetic resonance
imaging (MRI) have both been used for decades in cardiovas-
cular imaging. Since 2010, hybrid PET/MRI using sequential
and integrated scanner platforms has been available, with hy-
brid cardiac PET/MR imaging protocols increasingly incorpo-
rated into clinical workflows. Given the range of
complementary information provided by each method, the
use of hybrid PET/MRI may be justified and beneficial in
particular clinical settings for the evaluation of different dis-
ease entities. In the present joint position statement, we criti-
cally review the role and value of integrated PET/MRI in
cardiovascular imaging, provide a technical overview of car-
diac PET/MRI and practical advice related to the cardiac PET/
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MRI workflow, identify cardiovascular applications that can
potentially benefit from hybrid PET/MRI, and describe the
needs for future development and research. In order to encour-
age its wide dissemination, this article is freely accessible on
the European Radiology and European Journal of Hybrid
Imaging web sites.
Key Points
• Studies and case-reports indicate that PET/MRI is a feasible
and robust technology.
• Promising fields of application include a variety of cardiac
conditions.
• Larger studies are required to demonstrate its incremental
and cost-effective value.
• The translation of novel radiopharmaceuticals and MR-
sequences will provide exciting new opportunities.
Keywords Cardiac PET/MRI . CardiacMRI . Hybrid
imaging . Cardiac imaging . FDG
Introduction
Positron emission tomography (PET) and magnetic resonance
imaging (MRI) have both been used for decades in cardiovas-
cular imaging. Since 2010, hybrid PET/MRI using sequential
and integrated scanner platforms has been available, with hy-
brid cardiac PET/MR imaging protocols increasingly incorpo-
rated into clinical workflows [1].
Because of its robustness and broad range of imaging capa-
bilities, cardiacMRI (CMR) has become a standard of reference
for a variety of cardiovascular applications for different dis-
eases, including the quantification of left and right ventricular
dysfunction, the determination of global and regional wall mo-
tion abnormalities, and tissue characterisation (scar, fat, and
oedema), as well as valve function. On the other hand, PET is
superb at absolute quantification of myocardial perfusion and
coronary flow reserve as well as visualisation and quantification
of specific processes at themolecular level, such as metabolism,
inflammation, or innervation [2]. In fact, there is a range of
complementary information from each method, suggesting the
use of hybrid PET/MRI may be justified in a routine clinical
setting for evaluation of different disease entities [3].
However, there is also overlapping diagnostic information
provided by both modalities, so that the combined use of the
hybrid technique with regards to a potential incremental value
for both diagnostic purposes and individual risk stratification of
heart diseases has to be evaluated. For instance, both modalities
have proven their ability to assess myocardial perfusion or via-
bility, so that parameters coming from MRI or PET could be
prioritised to avoid redundant information and to shorten acqui-
sition protocols. Alternatively, specific imaging biomarkers could
be added to increase the complementary multiparametric readout
of the whole procedure. To elucidate the exact role and value of
integrated PET/MRI in cardiovascular imaging,we aimed to give
a technical overview of cardiac PET/MRI, provide practical ad-
vice related to the cardiac PET/MRI workflow, identify cardio-
vascular applications that can potentially benefit from hybrid
PET/MRI, and describe the needs for future development and
research. The content of this paper will be based on published
studies and available evidence, and if not yet available, on per-
sonal experience and expert opinion.
Technical considerations
Design of current PET/MRI systems
The combination of separate PETandMR scanners into a single
multimodality system necessitates a careful design of several
hardware components. MRI requires well-controlled and
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uniform static magnetic fields for spin polarisation, linear gradi-
ent fields for spatial signal encoding, and radiofrequency (RF)
fields for spin excitation and signal readout. Therefore, any
unshielded hardware can affect the accuracy and quality of MR
images. Furthermore, conventional PET detectors and associated
hardware are not compatible with strong electromagnetic fields.
In particular, conventional photomultiplier tubes (PMT), which
are needed to convert and amplify signal from scintillation crys-
tals into electronic signal, do not function properly in or near
these fields.
Integrating PET detectors based on PMT within an MR
system has proven to be a difficult task requiring some ven-
dors to physically separate the PET and MRI units. In the
context of hybrid PET/MRI, conventional PMT detectors
can only be used if the PET unit is placed sufficiently far from
the MRI unit to virtually eliminate deleterious interactions,
thus leading to a sequential system design [4]. In current inte-
grated PET/MRI systems interference is minimised using ei-
ther avalanche photodiodes (APD; Siemens Biograph mMR)
or silicon photon multipliers (SiPM; GE Signa PET/MR)
[5–8]. The performance of these semiconductor-based detec-
tors, used to replace conventional PMT, is not affected by
strong magnetic fields, which is a precondition for the design
of integrated PET/MRI systems.
Attenuation correction (AC) in PET/MRI
Without provisions, PETsystemsmiss certain coincidence events
because of absorption in dense tissue or scattering out of the
detector field of view (FOV). Thus, modern PET and PET/CT
systems use attenuation maps (μ-maps) that contain the
radiodensity of each voxel within the body volume for 511-
keV photons for the correction of acquired PET data. These are
typically calculated using transmission scans with external 68Ge
radionuclide sources or now increasingly using co-registered CT
data acquired at an energy level of 80-140 keV, which needs an
additional extrapolation to convert to the radiodensity of 511-
keV photons [9].
The practical consequence is that all PET data in hybrid
PET/MRI needs to be attenuation corrected during the data
reconstruction process in order to provide a valid quantification
of regional tracer activity in the imaged object. Both patient
tissues and PET/MRI system hardware components (e.g. the
systems patient table, MR radiofrequency coils, ECG equip-
ment) within the FOVof the PET detector during data acqui-
sition attenuate the number of true annihilation events and,
consequently, may lead to incorrect quantification results with-
out applying attenuation correction (AC) [7, 10]. Depending
on the relative position of the heart in the patient’s body, the
emitted photons experience different attenuation on their way
through the body to the PET detector. Thus, non-AC PET data
show significant underestimation of the tracer activity deep in
the patient’s body, including parts of the heart. Current system
implementations for attenuation correction in integrated PET/
MRI are realised in two ways: (1) The AC of patient tissues is
performed by using MR-based image information that is seg-
mented into different tissue classes and is assigned different
linear attenuation coefficients (LAC). (2) The AC of hardware
components is realised by using CT-based models that repre-
sent attenuating hardware (e.g. RF coils and the systems pa-
tient table) during the PET reconstruction [11].
AC of patient tissues
In integrated PET/MRI, the PETAC factors need to be derived
from the MRI data collected during a PET/MRI examination.
The most common approach uses a multi-point Dixon se-
quence for segmentation into lung, fat, soft tissue, and back-
ground [11] (Fig. 1).While this method is widely used and has
shown to provide robust results for MRI-based AC in whole-
body PET/MRI, this method does not segment bone and cal-
cification into a separate class, but classifies it as soft tissue,
which may result in underestimation of local attenuation
values close to bone. Consequently, standardised tracer uptake
close to bone may be underestimated [12], which could in
particular apply to the retrosternal parts of the heart.
Modified segmentation methods based on ultrashort echo
time (UTE) sequences are now also available that can segment
tissue with very short T2* (such as bone) into a separate class.
The application of UTE sequences for bone detection has been
shown to improve quantification in brain PET/MRI studies
[13–16]. However, due to a rather small field of view and
extended data acquisition times this technique is not yet usable
in clinical cardiac PET/MRI imaging. For whole-body and
cardiac PET/MRI imaging, the use of Dixon-based MR-AC
[11] in conjunction with recently developed patient-specific
atlas-based addition of major bones as a separate tissue class
seems to be a practical alternative for further improvement of
the current implementations of MR-based AC [17].
Because of lack of space within the magnet bore and rela-
tively long examination times, cardiac PET/MRI is usually per-
formed with the patient’s arms aligned along the body axis.
Depending on the patient’s body habitus, this can result in parts
of the arms being placed outside the MR FOV. This can cause
so-called truncation artefacts, which can at least partially be
corrected with PET emission data using maximum likelihood
reconstruction of attenuation and activity (MLAA) [18]. The
MLAA algorithm detects the contours of the arms in the PET
images utilising unspecific radiotracer uptake, which allows the
MR-based ACmap to be complemented with PET information.
This method is, however, limited when highly specific tracers
are used which do not accumulate over time in non-target tissue
such as the arms. An alternative method for truncation correc-
tion in MR-based AC has been proposed by Blumhagen et al.
Here the transaxial FOVof the AC map is increased from typ-
ically 50 cm to 60 cm by applying optimised readout gradients
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in MR imaging (B0 homogenisation using gradient enhance-
ment, HUGE) [19]. This method, based purely on MR infor-
mation, effectively helps to reduce the residual attenuation bias
in the thoracic region that might arise due to truncation artefacts
along the arms [20, 21] (Fig. 2).
AC of hardware components
In integrated cardiac PET/MRI, the patient is placed on top of a
rigid phased-array spine RF coil. For anterior signal detection,
a second body phased-array RF surface coil is placed on the
chest (Fig. 3). As attenuation of such instrumentation cannot be
derived from the available MRI data, all RF surface coils used
in the PET FOV during simultaneous PET data acquisition
have to be optimised for PET transparency [22–24].
The residual PET signal attenuation of rigid and stationary
equipment such as RF coils can be compensated by straightfor-
ward AC methods. Predefined attenuation maps (templates) for
the patient table and non-flexible RF coils thus are usually added
to the patient tissue attenuation map prior to the PET reconstruc-
tion. These templates are based on CT transmission scans of the
patient table or RF coils, providing an exact 3D representation of
the spatial distribution of attenuation factors in a virtual model of
the respective hardware component [24, 25]. By linking the
current patient table position during a patient examination to
the known position of the hardware component on the table,
template-based AC can be automatically performed during the
PET data reconstruction process [7, 22]. This method for hard-
ware component AC is an established standard in the current
commercially available PET/MRI systems.
For flexible surface RF coils such as the 6-channel RF body
phased array (Fig. 3), the AC must be performed differently.
Because the design is flexible, the individual position and
shape of this RF coil during a patient examination is not
known. Thus, a pre-acquired rigid 3D CT template cannot
directly be co-registered [24]. Here, MR-detectable markers
can be used to perform an automatic non-rigid co-registration
of the pre-acquired 3D CT attenuation template to the individ-
ual position and shape of the flexible RF during the cardiac
PET/MRI examination [26]. Coil position detection with
application of UTE sequences as an MR-based alternative
has turned out to be insufficient for large flexible RF coils [24].
The previous sections on attenuation correction illustrate the
complexity of performing AC in PET/MR imaging. In the lack
of a radioactive transmission source as, for example, the CT
scanner in PET/CT, or rotating 68Ge rod sources in former PET-
only systems, newmethods had to be developed to performAC
in the PET/MR environment [7]. As described in the previous
sections, AC in PET/MR is assembled from many modular
building blocks: Dixon sequences provide AC of the patient
soft tissues [11], UTE sequences [15, 16] or bone models [17]
provide AC of the major bones, pre-acquired CT-based tem-
plates provide AC of RF coils and other hardware components
[22–26], truncation correction may be based on MR images
(e.g. HUGE method) [19, 20] or based on PET images (e.g.
MLAAmethod) [18]. Numerous innovative solutions for atten-
uation correction and truncation correction have been suggested
and scientifically evaluated during the past years. Of these,
some of the most accurate and practical developments have
found their way from research applications into the most recent
product software applications of all PET/MR systems. Today,
attenuation correction in PET/MR whole-body imaging appli-
cations can be considered as largely solved in terms of robust-
ness and accuracy. Nevertheless, the modular setting requiring
the combination of multiple methods to achieve AC in PET/
MR renders the situation comparably complex when compared
to the “push-button” ease of use of performing AC in PET/CT.
Motion correction
MR-based correction of motion in PET data is a further theoret-
ical advantage of simultaneous PET/MRI acquisition, but it is
still a highly promising topic of ongoing research and, thus, not
yet implemented in clinical routine. In principle, the detection of
respiratory and cardiac motion as well as involuntary patient
movement using real-time 3D MRI and/or tagging techniques
can be used to compensate for such motion in simultaneously
acquired PET data [27]. Similarly, MRI-recorded 3D motion
correction can be used for improved PETAC, allowing counts
to be shifted before reconstruction [28, 29], increasing the
Fig. 1 Soft-tissue attenuation correction (AC) of 18F-FDG PET images
based on MRI. (A) Uncorrected thoracic PET scan showing relative
activity enhancement in the lungs and along the outer contours of the
patient. (B and C) 3D Dixon volume interpolated breath-hold
examination (VIBE) MR sequence providing separate water/fat “in-
phase” and “opposed-phase” images that serve as basis for soft-tissue
segmentation. (D) Segmented soft tissue groups (air, fat, muscle, lungs)
that can be assigned to a 3D PET attenuation map. (E) Resulting
attenuation corrected PET scan of the initial data set (A). Note: Bone
signal is assigned soft tissue values in this MRI-based approach for AC
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reliability of the PET data as compared to self-gated methods,
especially in low-dose/high-noise data [30, 31]. Once clinically
available, these techniques would however require integrated
scanners with the capacity of simultaneous image acquisition.
Image post-processing, visualisation, and quantification
Several software solutions, available from commercial and
academic sources, offer semi-automatic and automated pro-
cessing of cardiac imaging data. Most software products on
the market focus on either CMR or PET separately, but there
are increasingly software packages such as OsiriX (OsiriX
Foundation, Geneva, Switzerland), Munich-Heart (TU
München, Munich, Germany), and syngo.via (Siemens
Healthineers, Erlangen, Germany) available utilising both
PET and MRI data. However, software solutions for fully
integrated PET/MRI analyses are still missing. The following
sections provide an overview of potential clinical indications
for cardiac PET/MRI, which are also summarised in Table 1.
Ischaemic heart disease
Stable coronary artery disease
Stable coronary artery disease is among the major public health
issues of Western societies and has traditionally been perceived
as a consequence of the increasing narrowing of the coronary
due to accumulation of atherosclerosis that can be diagnosed by
coronary angiography and treated by percutaneous or surgical
coronary revascularisation [32]. However, in contrast to the
poor prognostic value of the morphologic severity of epicardial
stenoses only the evidence of the haemodynamic relevance of
coronary stenoses and/or the presence and extent of myocardial
perfusion defect represent an established criterion for clinical
outcome after revascularisation [33]. Despite some promising
recent developments in self-navigated acquisition techniques
[34] the detection and characterisation of coronary stenoses,
remains the cornerstone of computed tomography [32]; howev-
er, myocardial perfusion imaging by MRI has been well
established in clinical workflows and provides similar diagnos-
tic accuracy as SPECT [35]. Also, PET is used for myocardial
perfusion and in fact is widely considered the reference stan-
dard for non-invasive quantitative assessment of myocardial
perfusion [36, 88]. Most of the myocardial perfusion tracers
used in PET are produced onsite in cyclotrons, e.g. NH3 or
H2
15O, and have been extensively used in both research and
clinical applications.With introduction of generator-based 82Rb
PET based myocardial perfusion assessment is now also possi-
ble without an onsite cyclotron. With 82Rb the radiation dose is
low and the spatial resolution seems to be sufficient for routine
applications and has several advantages compared to SPECT-
based myocardial perfusion [37, 38]. However, current design
does not allow an easy workflow for 82Rb on a PET/MRI
Fig. 3 (A) 6-channel thorax radiofrequency coil that can be used for MR
signal reception during simultaneous cardiac PET/MR data acquisition.
Images (B and C) showMR-based attenuation maps of the patient tissues
that were acquired with a 3D Dixon sequence. The hardware attenuation
correction map of the flexible RF coil (orange/red) here was
automatically co-registered with non-rigid registration to the patient
tissue AC map using visible markers. Such attenuation maps represent
the geometric distribution of PET signal attenuating hardware and soft
tissue structures in the PET field of view during simultaneous PET and
MR data acquisition
Fig. 2 Truncation artefact correction in hybrid PET/MRI imaging. The
FOV in MR imaging is limited, leading to signal truncations in the MR-
based attenuation map (A, arrows along the arms). These signal
truncations cause an attenuation bias during attenuation correction
(under-correction). The HUGE technique increases the FOV in MR
imaging eliminating these artefacts (B, arrows). The fusion of truncated
attenuation map (A) and the HUGE images (B) shows this effect (C)
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system as the generators are not safe to be operated within a
strong magnetic field, novel 18F-labelled perfusion tracers with
a 110-min half-life, high first-pass extraction, and nearly linear
flow-related uptake were introduced [39] and quantitative as-
sessment of the transmural extension of perfusion defects has
been demonstrated [40]. However, these tracers are not yet
broadly available. Despite the promise of PET/MRI hybrid sys-
tems, there is currently no scientific evidence to support the
value of a combined PET/MRI approach for patients with stable
coronary artery disease, thus further research is warranted [41].
Acute coronary syndrome
Infarct size is a major predictor of outcome early after myo-
cardial infarction. Initial PET/MRI studies in the subacute
phase after acute myocardial infarction (AMI) have demon-
strated moderate to good agreement between myocardial seg-
ments showing LGE and reduced 18F-FDG uptake [42–44].
Furthermore,MRI in the subacute phase after reperfusedmyo-
cardial infarction is able to differentiate between myocardial
oedema, microvascular obstruction, and intramyocardial
haemorrhage as a potential indicator for reperfusion injury
with additional prognostic impact also for the right ventricle
[45–47].
Nevertheless, studies have observed a certain disagreement
between PET and MRI. In cases of relative underestimation of
infarct size using PET, this could be explained by the higher
spatial resolution of MRI and the resulting detection of
subendocardial infarction or a relative overestimation of infarct
size using CMR, as gadolinium has been shown to be also
entrapped in the surrounding oedema during the subacute phase
of myocardial infarction [48]. However, studies have identified
cases where some myocardial segments demonstrated reduced
18F-FDGuptake in PET, but no LGE inMRI. Thesemyocardial
segments had wall motion abnormalities and showed only par-
tial functional recovery after 6 months [44].
The discrimination between reversible and irreversible
myocardial dysfunction in the subacute phase after AMI is
of high clinical and scientific importance. From the clinical
perspective, reversible dysfunction of myocardial segments
will contribute to global left ventricular recovery. On the other
hand, dysfunction of non-infarcted myocardial segments in
peri-infarct regions is linked to the salvage area, that is, the
difference between the area at risk and the final infarct size. A
PET/MRI study in patients with reperfused AMI has found
that the area of reduced 18F-FDG uptake correlates with the
area at risk (as determined by the endocardial surface area)
and, in the absence of necrosis, is localised in the perfusion
territory of the culprit artery [42]. If confirmed by further
studies, the area of reduced 18F-FDG uptake could be used
as a surrogate parameter for the evaluation of strategies to
reduce infarct size, such as pre- and post- or remote
conditioning.
Finally, with the ability of hyperpolarised compounds, e.g.
13C-pyruvate, to reveal in real time further details on myocar-
dial substrate metabolism [49], and the recent demonstration
Table 1 Overview of potential
clinical indications for cardiac
PET/MRI
Potential Indication Comment
Strong Cardiac inflammation Detection and assessment of activity not satisfactory
using CMR; complementary information using
CMR and PET; high number of clinical cases
Strong Ischemic heart disease Established criteria for clinical outcome after
revascularisation not satisfactory; integration of
structural alterations and perfusion using
PET/MRI seems plausible; high number of
clinical cases with large combined morbidity and
mortality; to date highly speculative due to
missing data, particularly on the combination with
MR coronary angiography.
Strong Ischemic cardiomyopathy Limited evidence available for combined PET/MRI,
but generally great potential by assessing
perfusion, metabolism, viability and function
simultaneously. Strong potential for tissue
characterization by using novel
radiopharmaceuticals.
Intermediate Acute coronary syndromes Assessment of myocardial salvage and cardiac
remodelling could guide the development of
novel therapies; maybe limited relevance outside
research or clinical studies
Weak Cardiac tumours CMR or PET(/CT) probably sufficient in most cases;
anticipated added value of PET/MRI for planning
of complex surgery/radiation or identification of
relapse in malignant tumours
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of the feasibility of performing simultaneous PET and
hyperpolarised MR, a technique named hyperPET [50], car-
diac hyperPET on PET/MRI hybrid systems may become a
future application for integrated scanners.
Ischaemic cardiomyopathy
In patients with ischaemic cardiomyopathy, assessment of
myocardial viability and function is of paramount importance
for optimal patient management and further therapy planning.
A wide range of treatment options are available including
conservative medical treatment or revascularisation proce-
dures. The role of cardiac PET/MRI in these patients could
be the prospective identification of those patients who will
eventually benefit from revascularisation therapy, as these in-
vasive procedures are associated with significant
periprocedural morbidity and mortality [51] and, thus, could
be particularly useful in patients with reduced general condi-
tion due to congestive heart failure. For acquiring different
blood flow and viability parameters in one session, integrated
cardiac PET/MRI using dual tracer protocols such as 13N-NH3
and 18F-FDG combined with late gadolinium enhancement
(LGE) can be applied. These allow for accurate quantification,
localisation, and characterisation of the whole myocardium.
While LGE enables precise assessment of transmural and
even thin subendocardial scarring, simultaneous acquisition
of sequential 13N-NH3 and
18F-FDG PET scans can identify
and quantify myocardial areas with decreased perfusion or
contractility, but preserved viability, so called hibernating or
stunned myocardial tissue [52]. As LGE and 13N-NH3/
18F-
FDG provide different information, the interaction and com-
plementary value of both techniques could improve both in-
dividual risk assessment and prediction of patient outcome
(Fig. 4). In order to shorten imaging protocols and increase
efficiency, future studies will have to identify complementary
and redundant information yielded by the different techniques.
Once the optimal PET/MRI viability parameters are identi-
fied, redundant MRI sequences and/or PET tracers could be
omitted from the protocol. Also, since 13N-NH3 needs an
onsite cyclotron and is labour intensive to produce, the use
of other PET perfusions tracers for such combined studies
could be considered.
Since patients with ischaemic cardiomyopathy are at high
risk for developing ventricular arrhythmias and sudden cardiac
death, a PET tracer of myocardial innervation could be added to
the imaging protocol in these patients. Harms et al. have shown
in a very recent publication that myocardial blood flow and
myocardial innervation can be obtained from a single PET scan
using 15O-water and 11C-meta-hydroxyephedrine [53].
Myocardial perfusion-innervation mismatches are frequently
associated with increased mortality due to sudden cardiac arrest
[54]. Prospective studies with combined PET/MRI and inner-
vation tracers such as 11C-meta-hydroxyephedrine might,
therefore, be usable to depict cardiac sympathetic neuronal dys-
function and to deliver comprehensive information about the
denervated myocardium in patients with ischaemic cardiomy-
opathy, which are at increased risk of sudden cardiac death.
The main limitation of the current PET/MRI studies using
dual tracer protocols is the long scanning time of 60 min or
more, which may not be tolerated well by a subgroup of patients
with poor general state. Thus, the development of shortened
acquisition protocols remains a major goal of future research.
Inflammatory heart disease
In recent years, 18F-FDGPET has attracted growing interest in
the diagnosis and monitoring of inflammatory diseases, in-
cluding those of the heart [55]. CMR is an established com-
ponent in the clinical diagnosis and management of cardiac
inflammation [56–58]. With MRI it is possible to detect even
small areas of myocardial necrosis or fibrosis using LGE and
T1 mapping, to accurately detect regional and global dysfunc-
tion, to assess myocardial oedema and hyperaemia, as well as
pericardial effusion. Despite the availability of newer T1 and
T2 mapping techniques together with extracellular volume
(ECV) calculations to detect also diffuse inflammatory dis-
ease, there is still a lack of accuracy especially in patients with
chronic myocarditis [59]. However, in these patients with
chronic disease, specific MR-inflammation parameters such
as T2 mapping performed best. Given the specific character-
istics of MRI, a combination of multiparametric MRI with the
high sensitivity and outstanding quantification capabilities of
18F-FDG PET could represent a powerful imaging modality
for cardiac inflammation. Furthermore, a number of non-FDG
tracers targeting different aspects of inflammation reaching
from chemokine expression over cellular involvement to
changes in the myocardial tissue composition could add sig-
nificant value to cardiac PET/MRI in the future [60]. For 18F-
FDG PET imaging of myocardial inflammation it is important
to realise, that healthy myocardium utilises both glucose and
free fatty acids, depending on the patient’s nutrition and
fasting status. To achieve high contrast between inflammatory
infiltrates and normal myocardium, it is necessary to suppress
myocardial glucose metabolism, which can be obtained by
different protocols including prolonged fasting, high-fat low-
carbohydrate diet, fatty acid loading, and unfractionated hep-
arin loading [61–63]. However, fasting has been identified as
one major reason for patient discomfort, potentially contribut-
ing to increased cancellation rates during cardiac PET/MRI
examinations. A recent study has demonstrated a high-fat
low-carbohydrate protein-permitted diet without fasting to
yield an 84% success rate regarding suppression of normal
myocardial glucose uptake. Cancellation rate was less than
3% and thus comparable to routine CMR examinations [64].
Novel techniques such as ultrasmall superparamagnetic
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particles of iron oxide (USPIO)-enhancedMRI targeting mac-
rophage activity or 68Ga-labelled somatostatin receptor PET
imaging targeting activated lymphocytes hold the potential to
further improve cardiac PET/MR imaging of inflammation.
Myocarditis
To date, no studies but some case reports have been pub-
lished that evaluate PET/MRI for the imaging of myocar-
ditis. An initial report has demonstrated the use of 18F-
FDG PET /MRI in a case of myocarditis caused by par-
vovirus B19 [65], Figure 5. In this report, focal
subepicardial LGE was closely matched by intense 18F-
FDG uptake and accompanied by myocardial oedema and
hyperaemia. While MRI would have been sufficient for
the detection and diagnosis of myocarditis in this case, it
highlights the ability of PET to quantify inflammatory
activity, particularly with respect to disease monitoring.
A similar case was reported from a patient with myocar-
ditis due to Epstein-Barr virus infection with diffuse 18F-FDG
uptake in the lateral wall that again closely matched LGE and
myocardial oedema [66]. Besides monitoring of disease activ-
ity, integrated assessment using PET/MRI could increase diag-
nostic accuracy in cases with ambiguous MRI findings or im-
prove differentiation between acute and chronic/persistent myo-
carditis. Inflammatory cells can utilise a high amount of glucose
and, thus, might express high levels of glucose transporters and
increase hexokinase activity, leading to increased 18F-FDG up-
take in inflammatory infiltrates. As such, 18F-FDG uptake is
truly complementary to LGE (necrosis and oedema), T2-
weighted MRI (oedema) and early gadolinium enhancement
(hyperaemia) and could be useful to extend the well-known
“Lake Louise Criteria” in the non-invasive assessment of myo-
cardial inflammation in patients with suspected myocarditis
[67]. Despite the fact that myocarditis and pericarditis often
co-occur as so-called perimyocarditis, to date no studies or
reports on the use of PET/MRI in pericarditis have been pub-
lished. Still it seems plausible, that the detection and quantifi-
cation of active inflammation using PETcan here be considered
to be as much an opportunity as in myocarditis.
Cardiac sarcoidosis
Cardiac involvement is a strong predictor of poor outcome in
sarcoidosis, often manifesting in arrhythmia and heart failure.
Consequently, early detection of this complication—including
the differentiation between active and chronic disease—is a pre-
requisite for early treatment and thus can contribute to the re-
duction of overall morbidity and mortality. Commonly, treat-
ment not only comprises symptomatic management of cardiac
dysfunction, but also immunosuppressive therapy, which needs
to be carefully balanced against potential side effects. Thus,
besides early diagnosis, also continuous monitoring of disease
activity with the objective of drug titration is needed. However,
both accurate detection and monitoring of cardiac sarcoidosis
(CS) remain challenging, especially as endomyocardial biopsy
significantly suffers from sampling error and can cause severe
complications such as myocardial perforation. Hence, non-
Fig. 4 Cardiac PET/MRI of a 57-
year-old male patient with
advanced coronary artery disease
and deteriorated LV function
showing an agreement of missing
18F-FDG and 13N-NH3 uptakes
with presence of transmural late
gadolinium enhancement in the
anterior wall of the myocardium,
which was rated as transmural
scar. (A) Image fusion of 18F-
FDG PET and LGE MRI. (B)
Image fusion of 13N-NH3 PET
and LGE MRI. (C) Extent and
transmurality of scar determined
by MRI LGE
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invasive techniques such as CMR and 18F-FDG PET represent
interesting alternatives in the clinical workup of this disease
[67]. In fact, MRI and 18F-FDG PET both are recommended
for the assessment of CS [68]. CMR has been demonstrated to
predict death and other adverse events in suspected CS [69] and
a meta-analysis (seven studies, 164 patients) reported a pooled
89% sensitivity and 78% specificity for 18F-FDG PET in the
detection of cardiac involvement in sarcoidosis [70]. In a com-
parative study of CMR and 18F- FDG PET, MRI provided a
higher negative value and thus might be superior for ruling out
cardiac involvement [71].
However, there is already evidence that a combination of
both modalities might provide added value [75]. Both imaging
modalities in fact visualise different pathologic correlates of CS.
While LGE can accurately detect myocardial oedema necrosis
and fibrotic scar, 18F-FDG uptake is a quantifiably surrogate
parameter of increased glucose metabolism, a hallmark of in-
flammation. Thus, a combination of CMR and 18F-FDG PET
has the potential to provide both accurate detection as well as
assessment of disease activity. Several case reports have dem-
onstrated the feasibility of integrated 18F-FDG PET/MRI in the
detection [73, 74] and therapymonitoring [76] of CS. One study
in 51 consecutive patients with CS has found improved diag-
nostic accuracy of combined 18F-FDG PET/MRI over PET and
MRI alone [72]. Despite the sparseness of available studies,
integrated 18F-FDG PET/MRI holds great promise in the
imaging of CS. However, further evaluation, particularly with
respect to clinical outcome of patients is warranted.
Endocarditis
Endocarditis is a common complication after prosthetic valve
implantation. Complications of active inflammation include de-
hiscence of the valve, paravalvular leaks and abscesses. MRI
allows direct visualisation of the valve, identification and quan-
tification of regurgitations, and may spot separation of the aortic
valve from the aortic annulus [77]. Of note, artefacts arising
particularly from mechanical valves may have a severe impact
on image quality and diagnostic accuracy. In contrast to MRI,
18F-FDG PET allows the direct assessment of the predominant
site and acuity of inflammation and may also be utilised to
monitor therapy response after start of antimicrobial treatment.
An important prerequisite to increase specificity of 18F-FDG
PET is the effective suppression of physiologic, myocardial
18F-FDG uptake. Different patient preparation protocols (includ-
ing prolonged fasting, high-fat low-carbohydrate diet and pre-
injection of heparin before 18F-FDG administration) have been
proposed [78]. Furthermore, review of non-attenuated PET im-
ages is obligatory as metal extinction artefacts on MRI translate
into the attenuation correctionmap and cause underestimation of
the 18F-FDG uptake on attenuation-corrected PET images (in
contrast to metal artefacts in CT, which cause an overestimation
of tracer uptake on attenuation-corrected PET images) [79]. So
Fig. 5 18F-FDG PET/MRI in a
patient with acute viral
myocarditis caused by parvovirus
B19. (A) Late-gadolinium-
enhanced MRI long-axis view
demonstrating typical
subepicardial enhancement in the
anterior left ventricular wall that
was in excellent spatial agreement
with increased 18F-FDG uptake
on fused images (B). (C) T2-
weighted images revealed an
oedema in the LVanterior wall.
(D) Dynamic perfusion imaging
revealed hyperaemia in the LV
anterior wall. (With kind
permission from Ref 50-Nensa,
Poeppel 2014)
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far, to the best of our knowledge, no literature exists on the use
of integrated PET/MRI in infectious endocarditis. One case re-
port describes the successful use of 18F-FDG PET/MRI in a
patient suffering from Loeffler endocarditis [80].
Cardiac tumours
Given the role of MRI in the assessment of cardiac tumours and
the overall power of 18F-FDG PET in oncologic imaging, a
combination of both seems to be an attractive combination for
the diagnostic workup of cardiacmasses (Fig. 6). However, both
modalities alone have already been demonstrated to yield high
diagnostic accuracy in the assessment of malignancy [81],
which is one of the most important clinical questions for non-
invasive assessment before treatment. Nevertheless, integrated
assessment yielded improved diagnostic accuracy over PET- or
MR-only assessment in a small pilot study including 20 patients
with cardiac masses [82]. CMR has already been proven bene-
ficial in discriminating brown fat from pericardial metastasis
using its well-known tissue characterisation capabilities [76].
A recent JACC imaging vignette shows the potential of PET/
MRI in the diagnosis of cardiac and paracardiac masses with
histopathologic correlation [83]. Considering, the already strong
diagnostic performance of PET/CT and MRI, high cost, and
limited availability of PET/MRI scanners, integrated PET/MRI
imaging might be reserved for selected cases of cardiac tumours
were true benefit can be expected. Such cases could include the
planning of surgery in patients with complex cardiac infiltration
or the differentiation of scar tissue vs. relapse in follow-up ex-
aminations after surgery or radiation therapy [84]. However,
further evaluation with respect to costs and radiation exposure
is required.
Radiation exposure
The effective radiation dose for patients undergoing any
of the aforementioned procedures using standard PET
hardware (normally PET/CT) ranges between 1 and 7
mSv. However, acquisition times of the MRI component
are comparatively long. Depending on the half-life of the
respective radiotracer, PET acquisition times exceeding
twice the usual acquisition time without extension of the
overall scan time are possible for PET/MRI. 18F has a
half-life of 110 minutes. Thus, a significant reduction in
the administered activity (e.g. half of the usual activity)
seems prudent [85]. As a result, the effective radiation
doses are reduced by the same value. High-definition hy-
brid cardiac 18F-FDG PET/MRI has been shown to be
diagnostic using a mean activity of 150±70 MBq [64].
Compared to PET/CT, PET/MRI allows for further radia-
tion dose reduction due to the use of MRI data for
attenuation correction, which has been demonstrated to
be robust with an absolute mean difference of less than
2% for fat, muscles, and blood [86]. Furthermore, great
advances have been made in PET hardware using APDs
and SiPMs with improved image resolution, higher count
rate, and reduced sensitivity to electromagnetic fields
[87], introducing additional radiation dose reduction pos-
sibilities for PET/MRI. Doses go below doses that are
common in CT angiography and compete with what is
possible with the latest technology on dual source CT
using prospectively triggered high-pitch spiral acquisition
[88].
Pitfalls
Initial experience after approximately 7 years and several hun-
dred examinations applied at various sites worldwide has
demonstrated that integrated cardiac PET/MRI, although a
complex procedure, is a robust and reliable imaging modality
feasible for clinical routine diagnostics. However, we still rec-
ommend that a team of MRI and PET cardiac imaging spe-
cialists and technicians perform and interpret cardiac PET/
MRI, as basic knowledge about common pitfalls is crucial
for valid image interpretation.
Segmentation and misalignment errors
As the creation of μ-maps is based on segmentation of MR
data, the validity of attenuation-corrected PET data is di-
rectly dependent on the validity of the underlying segmen-
tation. MR image artefacts or unexpected behaviour of the
segmentation algorithm can cause more or less severe tis-
sue misclassification, compromising the validity of
attenuation-corrected PET data due to wrong attenuation
coefficients in the μ-map [89]. MR artefacts in cardiac
imaging frequently originate from foreign objects such as
implantable port systems, sternal wire cerclages, artificial
heart valves or artificial joint replacement of the humerus.
It is mandatory, that cardiac PET/MRI reading includes
visual inspection of the underlying μ-maps. If significant
errors are evident, findings in attenuation-corrected PET
data should be interpreted with caution and correlation
with uncorrected PET data should be performed.
Another typical AC-related issue results from patient mo-
tion. In a typical setting, the MR-based μ-maps are created in
the beginning of the study and are later used for the attenua-
tion correction of PET data that get continuously acquired
over time in list mode. If the patient significantly changes
body position following μ-map creation, this results in mis-
alignment between attenuation coefficients and PET data,
which can cause severe PET image artefacts and quantifica-
tion bias. As a simple workaround it is recommended to
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perform repeated μ-map creation, interleaved between main
MRI blocks. If patient motion is retrospectively detected, PET
and MR needs to be registered and the PET reconstruction to
be repeated. Alternatively, PET list-mode data can be truncat-
ed to an interval before or after patient motion and an appro-
priate μ-map can be selected for attenuation correction.
Patient preparation for 18F-FDG PET/MRI studies
Depending on the clinical question, myocardial metabolism
needs to be shifted towards free fatty acid or glucose
utilisation in cardiac PET imaging with 18F-FDG; thus, reli-
able patient preparation is of utmost importance [90]. It is
strongly recommended to perform detailed patient interviews
regarding the compliance to the preparation protocol before
tracer injection. In cases of incompliance, the PET/MRI ex-
amination can be postponed or certain countermeasures (e.g.
insulin injection, unfractionated heparin injection, fatty acid
loading) can be taken. In addition to interviews, it is recom-
mended to perform blood testing of glucose level. A sample
basic and inflammation focused imaging protocol for cardiac
PET/MRI is provided in Fig. 7.
Reporting
The procedure and the results of the cardiac PET/MRI study
should be documented in a consensus report by respective
PET and MRI specialists. The description of findings should
be performed in a combined fashion rather than as a separate
description of PETandMRI findings split in two sections. For
performing and reporting of both cardiac PET and MRI we
refer to the actual procedure guidelines [91–93]. Here we pro-
vide a brief summary with a special focus on integrated PET/
MRI. We recommend reporting four key elements in the con-
sensus report: (a) clinical information, (b) procedure descrip-
tion, (c) description of findings, and (d) summary.
Clinical information
The clinical information should include patient demographics
(age, gender, weight, height) andmedical history of the patient
(known cardiac and extracardiac diseases, clinical symptoms,
cardiovascular risk factors and history of prior events and
treatments). It should also describe the indication for the study
and the specific question of the referring physician.
Procedure description
Specific patient preparation (e.g. fasting or other dietary
precautions, glucose loading, unfractionated heparin load-
ing) and blood glucose level before FDG administration
should be documented as well as the name, dose and route
of administration of regulated non-radioactive drugs (e.g.
insulin adenosine) and contrast agents. Study-specific in-
formation should include the radiopharmaceutical, the
amount of injected activity in MBq, the route of
Fig. 6 (A) Cine MR image of an
angiosarcoma infiltrating the free
wall of the right ventricle and
atrium with adjacent pericardial
effusion. (B) 18F-FDGPETshows
intense but heterogeneous 18F-
FDG uptake within the tumour
and otherwise suppressed
myocardial 18F-FDG uptake by
the use of a high-fat low-
carbohydrate protein-permitted
diet. (C) The tumour
demonstrates heterogeneous and
overall moderate enhancement on
T1-weighted MRI after
intravenous application of
gadolinium-based contrast agent.
(D) Fused images show excellent
spatial agreement between PET
and MRI
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administration (intravenous) and the date and time of ad-
ministration. Information about the PET/MRI system
(type, manufacturer, field strength) and specific equip-
ment information (e.g. MR surface coils) should be spec-
ified. A description of the procedure should include the
time interval between administration of the tracer and the
start time of the data acquisition, as well as a short de-
scription of the MRI protocol used. If appropriate, the
type of stress protocol should be specified.
Description of findings
The location, extent and intensity of pathological tracer accumu-
lation or pathological tracer reduction related to normal cardiac
tissue should be reported with regard to the aforementioned
references and the recommendations for standardised myocardi-
al segmentation and nomenclature for tomographic imaging of
the heart [93]. The intensity of pathological tracer accumulation
or reduction could be weighted as mild, moderate or intense.
Quantitative measures of tracer uptake could be provided (e.g.
SUV/SUL, perfusion [mL/min/g],metabolic rate), especially if a
comparison to follow-up examinations is intended. Depending
on the clinical indication, the report should include data regard-
ing perfusion/viability/extent and transmurality of scar tissue,
left and/or right ventricular function analysis, analysis of region-
al wall motion and myocardial mass, as described in detail pre-
viously. It also may include ventricular dimensions, which cor-
relate to dimensions as measured in echocardiography to im-
prove comparability. Depending on the MRI protocol used, the
report should give detailed information about the localisation
and extent of structural abnormalities of themyocardium includ-
ing oedema, perfusion deficits, infarcts, microvascular obstruc-
tion, haemorrhage, and fibrosis. The relationship of relevant
findings on MRI to pathological tracer distribution should be
reported. Findings should be at least weighted as concordant/
matching or discordant.
Extracardiac findings (e.g. great vessels, mediastinum,
lung) should be reported as well.
Depending on availability, findings should be interpreted in
the context of other imaging examinations (e.g. CT, PET/CT,
SPECT/CT), MRI, coronary angiography, ultrasound) and
clinical data. Particularly, assessment of hibernating myocar-
dium frequently requires prior myocardial perfusion SPECT
or PET. Comparison with previous examinations should be
part of the report.
If appropriate, confounding factors that might influence the
sensitivity or specificity of the assessment should be men-
tioned, e.g. motion artefacts, susceptibility artefacts, undesired
distribution of the tracer (such as ubiquitous high or low 18F-
FDG uptake in the myocardium, depending on the aims of the
examination).
Summary
The study should be identified as normal or abnormal. The
specific questions asked of the referring physician should be
directly addressed. If possible, a definite diagnosis should be
stated. Joint approval from a radiologist and a nuclear medi-
cine specialist is encouraged. Document the communication
of urgent or emergency findings to referring physicians or
their representative.
Fig. 7 Sample basic and
inflammation focused imaging
protocol for cardiac PET/MRI
Eur Radiol (2018) 28:4086–4101 4097
Requirements for future clinical applications
PET/MRI shows high potential for innovation in cardiac imag-
ing, providing comprehensive anatomical, pathomorphological,
functional, and molecular information of the myocardium,
which might lead to improved diagnosis and therapy monitor-
ing of cardiac diseases. As a new addition to the palette of
advanced imaging modalities, integrated PET/MRI systems
need to be validated before a broader clinical application can
be accomplished [93].
There are multiple other issues remaining to be resolved and
the strengths of simultaneous image acquisition were not yet
sufficiently exploited. Further improvement ofMR-based atten-
uation- correction is needed to allow for more accurate PET
assessment. This will promote applications that—such as quan-
titative myocardial perfusion imaging—require quantitative
PET imaging. Also, partial volume andmotion corrections have
to be clinically implemented for more accurate, reproducible
and sensitive PET quantification for conventional and also for
novel molecular agents. This requires the setup of
multiparametric imaging protocols and specialised software
for the integrated reading of multiparametric PET/MRI studies.
In a second phase, efforts have been made to understand
the interrelationship between different PET and MRI parame-
ters with the aim to resign redundant information and to val-
idate the incremental value of potentially complementary pa-
rameters. It might for example not be necessary to estimate
stress/rest perfusion, scar tissue or LV functional values with
both techniques, PET and MRI, simultaneously. However,
prospective clinical trials, uni- or multi-centric, to demonstrate
added value regarding diagnosis, monitoring and most impor-
tantly patient outcome of certain parameters in a clinical set-
ting are still missing.
The next step could then be the optimisation of imaging
protocols for the most important indications and the evalua-
tion of multiparametric (integrated) PET/MR imaging against
hard clinical endpoints. Also, new areas in disease assessment
should be explored, including the possible application of PET/
MRI in the detection of disease which could not be de-
tected using PET or MRI separately, for example low sig-
nal to noise scans in chronic low-grade inflammation dis-
ease. In this respect, the opportunities of multiparametric
imaging need to be translated into diagnostic benefit to
justify the investments in this rather complex and expen-
sive technology.
Summary
Integrated PET/MRI is available since 2010 and several stud-
ies and case reports have demonstrated cardiac PET/MRI to be
feasible and robust. MR image quality is not compromised by
the PETcomponent andMR-based attenuation correction pro-
vides sufficient accuracy for most clinical applications. PET
performance is comparable to PET/CT in the majority of
cases. Promising fields of application include suspected coro-
nary artery disease, acute myocardial infarction, and heart
failure, inflammatory heart diseases such as myocarditis and
cardiac sarcoidosis, as well as cardiac tumours. However, larg-
er studies will have to demonstrate added value in comparison
with current standards of care. Further research, and not least,
economical review will have to clarify where integrated scan-
ners demonstrate a competitive advantage and where sequen-
tial PET and MR acquisition with post hoc image fusion with
software is good enough. Ongoing technical improvements
such as MR-based PET motion correction are anticipated
and will lead to higher spatial and temporal resolution, en-
abling advanced applications such as imaging of coronary
atherosclerosis. Finally, the translation of already existing
PET tracers from preclinical imaging into the clinical routine
will open up exciting new possibilities.
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